Introduction
Micro-RNAs are small non-coding RNAs that control genome expression by inhibiting translation and/or inducing degradation of specific target mRNAs (reviewed in Bartel, 2009) . They are encoded in the genome as dedicated polymerase II transcription units or in the introns of protein-coding genes. Small hairpin RNAs (pre-miRNAs) are excised from primary transcripts by the microprocessor, a complex composed of the RNase III Drosha (Lee et al., 2003) and the RNAbinding protein DGCR8 (Denli et al., 2004; Gregory et al., 2004; Han et al., 2004; Landthaler et al., 2004) . These 60-70 nt stem-loop RNAs are exported to the cytoplasm by exportin 5 (XPO5), where the loop is removed by the RNase III Dicer, producing a doublestranded RNA composed of the mature micro-RNA and a so-called miRNA*. The mature micro-RNA is then preferentially loaded on an RNA-induced silencing complex (RISC), and engages in the RNA interference pathway (Hutvagner et al., 2001) . These biogenesis steps are crucial because micro-RNA function has been found so far to be essentially controlled at the level of mature micro-RNA expression (Krol et al., 2010) .
Micro-RNAs are key players in the establishment and maintenance of cellular differentiation states, including stemness (Ivey and Srivastava, 2010) . Consistently, the expression profile of mature micro-RNAs is tissue specific. In transformed cells, this profile is sufficiently conserved to indicate the developmental origin of the tumor tissue (Lu et al., 2005) . However, a majority of micro-RNAs are downregulated in tumor tissues, probably reflecting the cellular dedifferentiation generally associated with transformation (Lu et al., 2005) . This downregulation is due at least in part to impairment of the microprocessor function (Thomson et al., 2006) . Among these downregulated micro-RNAs, several have been shown to be bona fide tumor suppressors (Calin et al., 2002; Mayr et al., 2007; Welch et al., 2007; Bonci et al., 2008; Cole et al., 2008; Esquela-Kerscher et al., 2008; Chen et al., 2009; Trang et al., 2010) . On the other hand, certain micro-RNAs are overexpressed in cancer. An oncogenic activity has been demonstrated for some of them, such as the miR-17-92 cluster (He et al., 2005) or miR-21 (Si et al., 2007; Asangani et al., 2008; Lu et al., 2008) , for which the term oncomiR was coined. Interestingly, miR-21-induced tumors are addicted to miR-21, that is, inhibition of miR-21 expression in established tumors resulted in tumor regression .
Prompted by the observed downregulation of a majority of micro-RNAs in tumors, Kumar et al. (2007) went on to show that impairing the micro-RNA pathway in transformed cells increased tumorigenesis, and that Dicer was an haploinsufficient tumor suppressor (Kumar et al., 2009) . Furthermore, certain cancer cell lines were shown to harbor inactivating mutations in TARBP2 (Melo et al., 2009) , an integral component of the Dicer complex, or XPO5 (Melo et al., 2010) . Both mutations diminished mature micro-RNA expression, and in both cases, re-expression of the wild-type protein was tumor suppressive. Altogether, these results built a picture in which decreased micro-RNA expression, a feature of undifferentiated cells, has protumorigenic properties. In contrast, blocking the micro-RNA pathway of embryonic stem (ES) cells impaired their growth (Murchison et al., 2005; Wang et al., 2007; Qi et al., 2009) . This global approach allowed to circumvent the often silent phenotype observed after inhibition of individual micro-RNAs (Miska et al., 2007; Wang et al., 2008) , a probable consequence of the structural and functional redundancy of these regulatory RNAs. In an elegant approach, Wang et al., (2008) went on by complementing this growth defect with individual micro-RNAs. This genetic screen identified ES cell growth-sustaining micro-RNAs, and through identification of their targets, revealed essential pathways controling the progression of ES cells in the cell cycle. Interestingly, several of these micro-RNAs share a common seed sequence with certain oncomiRs.
We hypothesized that cancer cells whose growth is dependent upon expression of oncomiRs should also respond to inhibition of the micro-RNA pathway by cell death or growth perturbation. Identifying such cells would support the concept of oncomiR addiction in cancer models not directly induced by exogenous oncomiR overexpression. Furthermore, it would provide with a genetic screen of growth-sustaining micro-RNAs in differentiated transformed cells. Herein, we report the identification of microprocessor-dependent cancer cell lines, and use thereof to screen for such micro-RNAs.
Results
An episomal shRNA system targeting the microprocessor It has been described previously that expressing genetargeting shRNAs from episomal vectors under the control of the H1 promoter is an efficient method of obtaining stable populations of homogenously knockeddown cells (see for instance Biard et al., 2005; Biard, 2007; Le May et al., 2010; Boehler et al., 2011) . We constructed a series of such vectors expressing shRNAs targeting either Drosha or DGCR8. These targets were chosen because, as required components of the same complex, their inhibition should induce similar phenotypes. Furthermore, in contrast with Dicer, the microprocessor is required for neither shRNA nor pre-miRNA maturation, allowing high efficiency of the knockdown, and subsequent complementation with individual premiRNAs. We first screened these vectors in HCT116 cells, as these cells have been described to withstand an impaired RNA interference pathway (Cummins et al., 2006) . We selected the most efficient shRNAs (shDro and shDG), as revealed by western blotting of Drosha and DGCR8 (Figure 1a) , and quantitative reverse transcription PCR (qRT-PCR) of a series of microRNAs (Figure 1b) . Of note, inhibiting Drosha induced overexpression of DGCR8, whereas inhibiting DGCR8 led to a decrease of Drosha expression ( Figure 1a ). This result confirmed the already identified cross-regulation between these two proteins (Han et al., 2009 ). In addition, Drosha kd HCT116 cells displayed an increased tumorigenesis capacity upon injection in immunocompromised mice (Figure 1c ), again in agreement with published results (Kumar et al., 2007) . We also selected two control shRNAs, one targeting a rare splice variant of Drosha (shDro sp ) and the other being a point mutant of shDG (shDGm; Figure 1a ). We concluded that the episomal vector strategy led to functional and stable knockdown of the microprocessor in non-clonal populations of transfected cells.
Identification of microprocessor-dependent cancer cells
To eliminate potential microprocessor-independent functions of the targeted proteins, as well as off-target effects of the selected shRNAs, we aimed at identifying cell lines in which both Drosha and DGCR8 knockdowns would diminish growth rates. Therefore, in a series of cancer cell lines, we attempted to obtain populations of cells expressing either shDro or shDG. However, we observed that certain cell lines, such as MCF-7, were unable to give rise to macroscopically visible clones after microprocessor knockdown (Figure 2a ). Microscopic examination of the plates revealed multiple clones of 5-10 adherent cells in both Drosha kd and DGCR8 kd MCF-7 plates (Figure 2b ). These clones could be maintained in culture for over 1 month without resuming growth. Flow cytometry DNA content analyses objectified a small but significant increase of the proportion of cells in the G0/G1 phase of the cell cycle ( Figure 2c ). However, staining for senescence-associated b-galactosidase activity was negative (Supplementary Figure 1) . This colony growth arrest was observed in other breast cancer cell lines (T47D and ZR75-1; Supplementary Figure 2 ), but not all (MDA-MB-231 and MDA-MB-157; Figure 2a and Supplementary Figure 2) , despite inhibition of both target protein and mature micro-RNA expression (Supplementary Figure 3 ). To ascertain that this colony growth arrest was due to the knockdown of the microprocessor, we first controlled that it could be reproduced with different shRNAs targeting Drosha or DGCR8 (Supplementary Screening for growth-sustaining micro-RNAs D Peric et al Figure 4 ). In addition, we attempted to complement inhibition of the endogenous DGCR8 with an exogenous RNA interference-resistant flagged version of DGCR8 (flag-DGCR8m; see Materials and methods). A population of MCF-7 cells expressing flagDGCR8m was established, then transfected with shDG or shDro, and selected for 15 days. These cells were able to grow to macroscopically visible clones after transfection of shDG, but not shDro (Figure 2d ). Alternatively, we reasoned that in microprocessor-dependent cells, DGCR8 inhibition should be sufficient to select for high flag-DGCR8m expression. We therefore co-transfected shDG and flag-DGCR8m, selected cells for shDG expression for 15 days, and analyzed flag-DGCR8m expression by western blotting. This led indeed to flagDGCR8m overexpression in MCF-7 cells, but not in MDA-MB-231 ( Figure 2e ). Therefore, we concluded that the observed colony growth arrest was actually due to microprocessor inhibition. Of note, the latter experiment also revealed that DGCR8 knockdowns were of similar efficiencies in the two cell lines, whereas quantification of Drosha and DGCR8 in growth-arrested cells was not reliable (personal results). Altogether, our data demonstrated that in certain cancer cells, inhibiting the microprocessor induced a long-term colony growth arrest, to which we will refer as CoGAM (Colony Growth Arrest induced by Microprocessor inhibition).
miR-19 and miR-20 are major CoGAM-complementing micro-RNAs in MCF-7 cells We then attempted to rescue CoGAM with single microRNAs, as assayed by the capacity for microprocessordepleted cells to grow to macroscopically visible clones in the presence of a single micro-RNA. For microprocessor-independent micro-RNA expression, we constructed a series of episomal vectors with a different selection marker (hygromycin instead of puromycin), each coding for a unique pre-miRNA under the control of the H1 promoter (see Materials and methods). Each vector was tested for its capacity to induce mature micro-RNA expression by transient transfection in HeLa cells, followed by qRT-PCR (Supplementary Table 1 ). We then co-transfected MCF-7 cells with the shDro coding vector (pEBP-shDro) and an equal amount of a single pre-miRNA coding vector (pEBHmiRx), and assayed for outgrowth of visible clones under puromycin and hygromycin selection. Under these settings, shDro expression also led to colony growth arrest when co-transfected with pEBH, or with the majority of the pre-miRNA coding vectors ( Figures  3a and b) . We also noted that two pre-miRNAs, prelet-7g and pre-miR-92, inhibited colony formation even without Drosha knockdown ( Figure 3a) . Strikingly, we identified pre-miRNAs that were capable of rescuing CoGAM on their own (Figures 3a and 3b ). In particular, pre-miR-19a (Po10 À4 vs pEBH), premiR-19b (Po10 À4 ) and pre-miR-20a (Po10 À7 ), three members of the oncogenic miR-17-92 cluster, allowed growth of multiple clones of Drosha kd cells. This was also the case for pre-miR-27b (Po10 À4 ), pre-miR-33a , a rare splice variant of Drosha; DG, DGCR8; DGm, a point mutant of shDG), and grown under selection for 2 weeks. Whole-cell extracts were analyzed by western blotting for Drosha and DGCR8 expression. GRP94 was used as a loading control. Although some irrelevant lanes have been deleted, all the presented lanes were from the same blot. (b) Total RNA was extracted from HCT116 cells transfected with a plasmid coding for shDro (pEBP-shDro) or an empty vector (pEBP). Expression of a series of mature micro-RNAs was quantified by qRT-PCR using RNU48 as a normalization target. (flagDGCR8m) were transfected with vectors coding for the indicated shRNAs, and treated as in (a). (e) MDA-MB-231 or MCF-7 cells were co-transfected with 0.2 mg of pEBP-shDG and 1.8 mg pCMV-flagDGCR8m, and grown for 2 weeks with puromycin selection (targeting only pEBP-shDG). Whole-cell extracts were analyzed for DGCR8 expression by western blotting. GRP94 was used as a loading control. Identification of the top band as flagDGCR8m was confirmed by hybridization with an anti-flag antibody (not shown). The experiment was performed three times with similar results. of the number of independent experiments indicated in brackets after the name of the complementing pre-miRNA. Statistical significance was calculated with a one-tailed Student's t-test vs complementation with the empty vector; ***Po10 À4 , **Po10 À2 and *Po5 Â 10 À2 (c) MCF-7 cells were transfected with pEBP-shDro and the indicated pEBH-miRx, grown under selection for 8, 12 and 18 days (D8, D12 and D18, respectively) and then fixed and stained with methylene blue. Colony numbers were quantified and are presented as mean ± s.d. of two independent experiments, except for empty (n ¼ 3) and miR-100 (n ¼ 1). Note that the small decrease in colony number upon complementation with miR-20a at day 18 is because of counting saturation (Supplementary Figure 5) . Figure 5) . Among complementing pre-miRNAs, two were able to sustain clone growth up to 20 days after transfection (pre-miR20a and pre-miR-27b; Figure 3c and Supplementary  Figure 6 ). In contrast, pre-miR-19, pre-miR-302 and Figure 3c and Supplementary Figure 6 ). These time-course experiments also confirmed that, contrary to pre-miR-27b, pre-miR-27a was not able to complement CoGAM (Figure 3c and Supplementary Figure 6) , although both pre-miRNAs similarly inhibit growth of control cells (Figure 3a) .
CoGAM is independent of the p53/p21 pathway The two major CoGAM-complementing micro-RNAs, miR-19 and miR-20, have also been reported to rescue the slow growth of DGCR8 ko ES cells, in part through inhibition of the p21 G1 checkpoint protein (Wang et al., 2008) . As CoGAM was accompanied by an increase in the proportion of cells in G0/G1 (Figure 2c) , we hypothesized that it involved p21 activation. We therefore constructed a hygromycin-selectable vector coding for a p21 targeting shRNA (pEBH-shp21), which we co-transfected with pEBP-shDro. After double selection, no visible clones could be observed (Supplementary Figure 7) . To ascertain the efficiency of p21 knockdown, we established a population of MCF-7 cells stably expressing shp21. These cells were deficient in p21 expression, even after ultraviolet treatment (Figure 4a ), but were still unable to grow after Drosha knockdown ( Figure 4b ). As p53 is a major transcriptional regulator of p21, we also tested the effect of Drosha knockdown in p53 kd cells (Desaint et al., 2004) . Western blotting confirmed the absence of p53 in one clone of pSU-PER-shp53-transfected MCF-7 cells, even after ultraviolet treatment (Figure 4c ). Although p53 knockdown slightly increased cloning frequency, Drosha inhibition was still able to induce growth arrest (Figure 4d ). In addition, we noted that CoGAM could be observed in T47-D cells (Supplementary Figure 2) , where p53 is known to be mutated (Runnebaum et al., 1991) . We concluded that CoGAM was resistant to inhibition of the p53/p21 axis.
The tumor suppressor phosphatase and tensin homologue deleted on chromosome 10 (PTEN) is involved in CoGAM The tumor suppressor PTEN, a major inhibitory regulator of the PI3K/AKT proliferation signaling pathway (Carracedo and Pandolfi, 2008) , is also a shared target of miR-19 (Lewis et al., 2003) and miR-20 (Poliseno et al., 2010) . In addition, in MDA-MB-231 cells, the PTEN protein was actually significantly increased by Drosha knockdown (Figure 5a ), a result that was confirmed at the mRNA level ( Supplementary  Figure 8) . To test for the involvement of PTEN in CoGAM, we constructed a hygromycin-selectable episomal vector coding for a PTEN targeting shRNA (pEBH-shPTEN). Upon transfection in MCF-7 cells, pEBH-shPTEN induced a decrease in PTEN expression and an increase in the phosphorylated form of AKT (Figure 5b ). Strikingly, pEBH-shPTEN was able to rescue the colony growth arrest induced by pEBPshDro (Figure 5c ). Although Drosha kd -PTEN kd cells did not grow to clones of similar size as controls, this result showed that PTEN is involved in the colony growth arrest induced by Drosha knockdown in MCF-7 cells.
Discussion
The results presented herein demonstrate that inhibiting the microprocessor results in growth arrest in certain Screening for growth-sustaining micro-RNAs D Peric et al cancer cell lines (Figure 2 ). Beyond the novelty of this observation, the experimental system that we designed, based on shRNA and pre-miRNA expression from episomal vectors, allowed to set up a positive screen for identification of growth-sustaining micro-RNAs in microprocessor-dependent cells (Figure 3 ). In its turn, this identification could be used as a starting point for hypothesis-driven strategies aimed at characterizing major growth-regulatory genes in CoGAM-sensitive cancer cells (Figures 4 and 5) . The fact that microprocessor inhibition can result in growth arrest had not been reported so far. On the contrary, impairing the micro-RNA pathway has been reported to increase tumorigenesis of transformed cells (Kumar et al., 2007 and Figure 1) , and mutations in at least three proteins involved in micro-RNA function (XPO5, TARBP2 and DICER) have been found to be functionally involved in tumorigenesis and/or tumor biology (Kumar et al., 2009; Melo et al., 2009 Melo et al., , 2010 . A major question is whether these different phenotypes resulted from quantitative or qualitative differences. Precise quantification of knockdown efficiencies in arrested cells was not possible, at the level of either targeted protein inhibition or mature micro-RNA expression. Although flag-DGCR8m-complemented DGCR8 kd cells revealed comparable levels of DGCR8 knockdown in MDA-MB-231 and MCF-7 cells, we cannot exclude that the rescue in itself modifies DGCR8 expression. As a matter of fact, less efficient Drosha targeting shRNAs did not induce growth arrest in MCF-7 cells (personal observations), showing that microprocessor inhibition must reach a threshold to induce growth arrest, even in CoGAM-sensitive cells. On the other hand, cell-specific phenotypes of approaches targeting the micro-RNA pathway are consistent with the cell specificity of growth-sustaining pathways and micro-RNA expression profiles. In this regard, the fact that the three CoGAM-sensitive cell lines were from breast carcinoma of the luminal type, whereas two basallike breast carcinomas were CoGAM resistant, although correlative at this point, supports the concept of a cell specificity of CoGAM sensitivity. In addition, the fact that Drosha kd -PTEN kd MCF-7 cells are able to grow, even at slow rate, confirms that induction of colony growth arrest by micro-RNA depletion depends upon the cellular background. We also note that complete inhibition of the micro-RNA pathway in ES cells (Murchison et al., 2005; Wang et al., 2007; Qi et al., 2009) , or adult tissues (Giraldez et al., 2005; Chong et al., 2008; Hand et al., 2009) , did not induce growth arrest. We conclude that CoGAM requires efficient microprocessor knockdown in a specific cellular background.
It should also be noted that the microprocessor is able to target and cleave the DGCR8 mRNA (Han et al., 2009; Kadener et al., 2009; Triboulet et al., 2009) . Although targeting of other mRNAs by the microprocessor (Kadener et al., 2009 ) is still controversial (Shenoy and Blelloch, 2009 ), we cannot exclude that inhibiting Drosha or DGCR8 could modify the expression of non-pri-miRNA RNAs.
Complementation experiments revealed similarities between the experimental model we present and the DGCR8 ko murine ES cell system (Wang et al., 2008) . In both cases, miR-19 and miR-20, as well as certain micro-RNAs sharing the miR-20 seed (from the miR-302 family, the murine miR-290 family and the human miR-372 family), or the miR-19 seed (miR-33), were found to rescue the phenotype induced by microprocessor inhibition. This is consistent with both phenotypes involving control of cell growth, and these micro-RNAs targeting multiple cell growth inhibitory genes. Interestingly, in both cases, miR-17 did not efficiently rescue the growth defect, although miR-17-5p and miR-20a share the same seed. This observation points to functional differences between homologous micro-RNAs, as also observed for miR-19a and miR19b in DGCR8
ko ES cell rescuing (Wang et al., 2008) , or Screening for growth-sustaining micro-RNAs D Peric et al for pre-miR-27a and pre-miR-27b in CoGAM rescuing (this manuscript). In the latter case, it appeared puzzling to attribute the marked functional difference to the single outside-the-seed nucleotide difference between miR-27a and miR-27b. We therefore note that, although this hypothesis has still to be tested, our data could also be explained by functional expression of miR-27b*. Indeed, (i) the miR expression system that we used is designed to lead to expression of the natural premiRNA, including the miR* part; (ii) miR-27b* and miR-27a* differ by several nucleotides, including one point mutation in the seed and (iii) miR-27b* is actually expressed in vivo, as shown by miR-27b/miR-27b* ratios of around 10 (Kuchenbauer et al., 2011) . On the other hand, we also detected a series of specificities that differentiated the ES cell-based screen from our data: (i) ES cell-expressed micro-RNAs (miR-302, miR-372/3) were found to rescue CoGAM less efficiently than miR-19 and miR-20, a difference that was not detected by complementation of DGCR8 knockout in ES cells; (ii) the rescuing effects of miR-19b and miR-27b appeared specific for CoGAM and (iii) p21, which participates in the growth inhibition observed in DGCR8 ko ES cells, is not involved in CoGAM. Altogether, these comparisons extend the major growth control function of microRNAs bearing the miR-19 or miR-20 seeds from stem cells to cancer cells. They also point to differences in the growth-regulatory pathways of ES cells and CoGAM-sensitive cancer cells, which deserve further investigation.
The identification of PTEN as a growth-regulatory protein involved in CoGAM is presented as an example of a hypothesis-driven approach based on the results of the micro-RNA functional screen that we describe. PTEN was chosen as a candidate because (i) it is a shared target of miR-19 and miR-20a; (ii) small modifications of PTEN expression have important functional consequences (Alimonti et al., 2010) , suggesting that deregulation of the micro-RNA level of regulation could be sufficient for a role in CoGAM induction and (iii) PTEN overexpression is known to inhibit growth of MCF-7 cells through induction of a G1 arrest (Weng et al., 1999) . Clearly, complementation of Drosha knockdown by PTEN knockdown is only partial, and less efficient than miR-19 or miR-20 complementation. Differences in the complementation phenotype were also observed between miR-19 and miR-20 (transient vs sustained colony outgrowth; Figure 3b ). These results are consistent with miR-19 and miR-20-complementing CoGAM through multiple targets, some shared, including PTEN, and some specific. They do, however, demonstrate that PTEN is involved in the regulation of growth-sustaining pathways in MCF-7 cells. In addition, they are consistent with a functional importance of oncomiRs in MCF-7, and consequently of the tumor suppressive consequences of microprocessor inhibition.
In summary, we have shown that certain cancer cells are dependent upon the microprocessor for their growth, and we have provided a simple positive screen to identify growth-sustaining micro-RNAs. This approach circumvented the problems linked to structural and functional redundancy of micro-RNAs, and was able to unveil functional specificities of homologous micro-RNAs. Obviously, characterization of other phenotypes in microprocessor-inhibited cancer cells could open new possibilities to functionally characterize micro-RNAs by direct phenotypic complementation.
Materials and methods

Cell culture
Cell lines used were as follows: A549 (lung carcinoma), HCT116 (colon carcinoma) and its p53 À/À derivative, HeLa (cervix carcinoma), MCF-7 (breast carcinoma), MDA-MB-157 (breast carcinoma), MDA-MB-231 (breast carcinoma), T-47D (breast carcinoma) and ZR75-1 (breast carcinoma). They were maintained in Dulbecco's modified Eagle's mediumGlutamax-I (Invitrogen, Cergy-Pontoise, France) supplemented with 10% fetal bovine serum (Biological Industries, ATGC, Marne-la-Valle´e, France) at 37 1C in a 5% CO 2 humidified atmosphere. Transfections were performed in 3.5 cm petri dishes at 80% confluency with 2 mg plasmid and 2 ml lipofectamine 2000 (Invitrogen). Cells were then seeded at 1/50 in 6 cm petri dishes and grown under selection for 14 days, unless otherwise indicated. Double transfections were performed the same way with 1.5 mg of each plasmid and 3 ml lipofectamine 2000, and cells were diluted 1/20th in 6 cm petri dishes for selection. Populations of transfected cells were established by pooling at least 100 clones after transfection and selection.
Complementation screen Double transfections were performed as described above. After 14 day selection, plates were fixed for 2 h in 4% formaldehyde and stained overnight with methylene blue in 30% methanol. They were then washed in water and air dried. Dried plates were pictured with a Bio-Print system (Vilber Lourmat, Marne-laValle´e, France). Colonies were quantified with a ColCount system (Oxford Optronics, Oxford, UK) with a manufacturerprovided sensitivity setting ('disperse-colonies').
Plasmids
The H1 promoter-containing Epstein-Barr virus plasmids (pEBP for puromycin selection and pEBH for hygromycin selection) have been described previously (Biard et al., 2005) . Individual shRNA or pre-miRNA coding plasmids were constructed by inserting hybridized oligonucleotides (Sigma, Lyon, France) into BglII-HindIII digested vectors. Oligonucleotide sequences were established by using the Dharmacon web site for shRNAs (http://www.dharmacon.com/Design Center/DesignCenterPage.aspx) and the miRBase web site for pre-miRNAs (http://www.mirbase.org/), and are available upon request. To ensure correct processing of the vectorencoded pre-miRNAs, we inserted the exact pre-miRNA sequences as shown in miRBase (that is, the 5 0 stem indicated in purple followed by the loop and the 3 0 stem indicated in purple) immediately after the well-defined transcription start site of the H1 promoter (as described in Brummelkamp et al., 2002) . Polymerase III will then lead to transcription of this sequence into a stem-loop RNA, which will require only cleavage by Dicer to remove the loop and produce the natural miR/miR* duplex. Plasmids were systematically sequenced (Millegen Biotechnologies, Labe`ge, France).
The pCMV-3 Â flagDGCR8m vector was constructed by ligating the PCR-amplified mmDGCR8 cDNA into pCMV-3 Â flag-10 (Sigma). Three mutations (T1642C, G1649C and T1651C) were introduced using the Quickchange Lightning site-directed mutagenesis kit (Agilent Technologies, Massy, France), leading to one conservative change (V435L). The insert was fully sequenced (Millegen Biotechnologies).
Western blotting
Total proteins were extracted in Tris 50 mM pH 8, NaCl 300 mM, Triton X-100 1%, sodium dodecyl sulfate 0.1%, ethylenediaminetetraacetic acid 1 mM, Complete protease inhibitor cocktail (Roche, Meylan, France) and phenylmethanesulphonyl-fluoride 1 mM, supplemented with PhosSTOP (Roche) where indicated. Lysates were cleared by centrifugation at 15 000 r.p.m. for 10 min at 4 1C, and protein content assayed using the Pierce micro-BCA kit (Thermo Fisher Scientific, Brebie`res, France). Proteins were separated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred on nitrocellulose or polyvinylidene difluoride membranes. Specific proteins were detected by incubation with the following antibodies: anti-PTEN (Cell Signaling Technology no. 9559, Beverly, MA, USA), anti-Phospho-Akt (S473; Cell Signaling Technology no. 4060), anti-Akt (Cell Signaling Technology no. 9272), anti-a-tubulin (Sigma no. T5168), anti-Drosha (Millipore nos. 07-717, Molsheim, France), anti-DGCR8 (Protein Tech Group no. 60084-1-Ig, Chicago, IL, USA), anti-GRP94 (Santa Cruz Biotechnology no. sc-11402, Le Perray en Yvelines, France), anti-glyceraldehyde phosphate deshydrogenase (Santa Cruz Biotechnology no. sc-20357), anti-p21 (Santa Cruz Biotechnology no. sc-6246) and the DO-7 anti-p53 monoclonal antibody (Santa Cruz Biotechnology no. 47698). Blots were revealed with either enhanced chemiluminescence þ (GE Healthcare, Orsay, France) and film exposure, or enhanced chemiluminescence Advance (GE Healthcare) and camera capture (G:Box, Syngene, Cambridge, UK). Quantification was performed with ImageQuant (GE Healthcare).
RNA extraction and micro-RNA qRT-PCR Total RNA was extracted using the miRNeasy kit (Qiagen, Courtaboeuf, France), and its quality was checked by calculating the optical density (OD) 260 /OD 230 (>2) and OD 260 /OD 280 (>1.8) ratios, and by agarose electrophoresis. Micro-RNAs were quantified by triplicate qRT-PCR using the Taqman micro-RNA assay (Applied Biosystem, Courtaboeuf, France). Relative quantification was performed using the DDCt method, using RNU48 as a reference.
Growth in athymic mice
Exponentially growing cells were trypsinized, washed once in phosphate-buffered saline supplemented with 10% fetal bovine serum and twice in phosphate-buffered saline, before subcutaneous injection into the flanks of athymic mice (NMRI nude mice, Janvier, Le Genest Saint Isle, France). Tumor volumes were calculated by multiplying two perpendicular measures, taken three times a week for the following 41 days, or until tumor size precluded it.
Cell cycle analysis (Colmont et al., 2001 ) and senescenceassociated b-galactosidase staining (Dimri et al., 1995) were performed as described elsewhere.
